US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

Soft tissue repair company Aroa could unlock $1.6b market
Markets

Soft tissue repair company Aroa could unlock $1.6b market

A transformational year is predicted for Aroa with maiden profit predicted.

Pūkaki mega-lake never seriously considered
Markets

Pūkaki mega-lake never seriously considered

Officials' idea for a giant lake would have cost billions and had serious impacts.

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Graham Skellern 03 Jul 2024
Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.